Mark Leibowitz

989 total citations
16 papers, 522 citations indexed

About

Mark Leibowitz is a scholar working on Pharmacology, Psychiatry and Mental health and Molecular Biology. According to data from OpenAlex, Mark Leibowitz has authored 16 papers receiving a total of 522 indexed citations (citations by other indexed papers that have themselves been cited), including 5 papers in Pharmacology, 4 papers in Psychiatry and Mental health and 3 papers in Molecular Biology. Recurrent topics in Mark Leibowitz's work include Pain Management and Opioid Use (2 papers), Poisoning and overdose treatments (2 papers) and Pharmacology and Obesity Treatment (2 papers). Mark Leibowitz is often cited by papers focused on Pain Management and Opioid Use (2 papers), Poisoning and overdose treatments (2 papers) and Pharmacology and Obesity Treatment (2 papers). Mark Leibowitz collaborates with scholars based in United States, United Kingdom and Switzerland. Mark Leibowitz's co-authors include Larry Ereshefsky, S. S. Jhee, Gilbert Lefèvre, Albert Enz, Heinz Schmidli, G Sędek, F. Pommier, Silke Appel‐Dingemanse, Michael A. Derby and David Hoelscher and has published in prestigious journals such as Neurology, Antimicrobial Agents and Chemotherapy and Clinical Pharmacology & Therapeutics.

In The Last Decade

Mark Leibowitz

16 papers receiving 502 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Mark Leibowitz United States 11 185 112 108 98 77 16 522
Jasper Kamp Netherlands 12 242 1.3× 66 0.6× 98 0.9× 26 0.3× 86 1.1× 14 509
I. Gaertner Germany 12 171 0.9× 50 0.4× 320 3.0× 51 0.5× 156 2.0× 13 715
Ya Miao China 15 66 0.4× 144 1.3× 79 0.7× 24 0.2× 55 0.7× 33 556
Randall J. Mack United States 15 219 1.2× 133 1.2× 404 3.7× 40 0.4× 92 1.2× 48 939
J.-J. Péré France 8 164 0.9× 78 0.7× 238 2.2× 67 0.7× 35 0.5× 12 439
G Sędek Switzerland 15 213 1.2× 85 0.8× 184 1.7× 203 2.1× 66 0.9× 26 659
Montastruc Jl France 14 57 0.3× 161 1.4× 61 0.6× 201 2.1× 160 2.1× 87 686
Didier Meulien United States 14 144 0.8× 95 0.8× 309 2.9× 74 0.8× 108 1.4× 25 606
Luciane Bisognin Ceretta Brazil 11 54 0.3× 82 0.7× 70 0.6× 45 0.5× 49 0.6× 44 495
Liara Rizzi Brazil 7 52 0.3× 177 1.6× 187 1.7× 41 0.4× 28 0.4× 19 588

Countries citing papers authored by Mark Leibowitz

Since Specialization
Citations

This map shows the geographic impact of Mark Leibowitz's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark Leibowitz with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark Leibowitz more than expected).

Fields of papers citing papers by Mark Leibowitz

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark Leibowitz. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark Leibowitz. The network helps show where Mark Leibowitz may publish in the future.

Co-authorship network of co-authors of Mark Leibowitz

This figure shows the co-authorship network connecting the top 25 collaborators of Mark Leibowitz. A scholar is included among the top collaborators of Mark Leibowitz based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mark Leibowitz. Mark Leibowitz is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

16 of 16 papers shown
1.
Leibowitz, Mark, et al.. (2024). Co-ML: Collaborative Machine Learning Model Building for Developing Dataset Design Practices. ACM Transactions on Computing Education. 24(2). 1–37. 8 indexed citations
2.
Bieck, P. R., Mark Leibowitz, D. Richard Lachno, et al.. (2016). Dihydroxyphenylglycol as a Biomarker of Norepinephrine Transporter Inhibition by Atomoxetine. Journal of Clinical Psychopharmacology. 36(6). 675–683. 6 indexed citations
3.
Furey, Sandy A., Steven Hull, Mark Leibowitz, Shyamalie Jayawardena, & Thomas Roth. (2014). A Randomized, Double-Blind, Placebo-Controlled, Multicenter, 28-Day, Polysomnographic Study of Gabapentin in Transient Insomnia Induced by Sleep Phase Advance. Journal of Clinical Sleep Medicine. 10(10). 1101–1109. 25 indexed citations
4.
5.
6.
7.
Addy, Carol, C. Assaid, David Hreniuk, et al.. (2009). Single‐Dose Administration of MK‐0657, an NR2B‐Selective NMDA Antagonist, Does Not Result in Clinically Meaningful Improvement in Motor Function in Patients With Moderate Parkinson's Disease. The Journal of Clinical Pharmacology. 49(7). 856–864. 51 indexed citations
8.
Jhee, S. S., Mark Yen, Larry Ereshefsky, et al.. (2008). Low Penetration of Oseltamivir and Its Carboxylate into Cerebrospinal Fluid in Healthy Japanese and Caucasian Volunteers. Antimicrobial Agents and Chemotherapy. 52(10). 3687–3693. 47 indexed citations
9.
Zhang, Lu, Jill Chappell, Celedon Gonzales, et al.. (2007). QT Effects of Duloxetine at Supratherapeutic Doses: A Placebo and Positive Controlled Study. Journal of Cardiovascular Pharmacology. 49(3). 146–153. 52 indexed citations
10.
Lefèvre, Gilbert, G Sędek, S. S. Jhee, et al.. (2007). Pharmacokinetics and Pharmacodynamics of the Novel Daily Rivastigmine Transdermal Patch Compared With Twice-daily Capsules in Alzheimer's Disease Patients. Clinical Pharmacology & Therapeutics. 83(1). 106–114. 106 indexed citations
11.
Derby, Michael A., Lu Zhang, Celedon Gonzales, et al.. (2007). The Effects of Supratherapeutic Doses of Duloxetine on Blood Pressure and Pulse Rate. Journal of Cardiovascular Pharmacology. 49(6). 384–393. 30 indexed citations
12.
Rosen, Laura, Julie A. Stone, Andrew Plump, et al.. (2006). O4–03–02: The gamma secretase inhibitor MK–0752 acutely and significantly reduces CSF Abeta40 concentrations in humans. Alzheimer s & Dementia. 2(3S_Part_3). 28 indexed citations
13.
Jhee, S. S., et al.. (2004). Similarity of Insulin Detemir Pharmacokinetics, Safety, and Tolerability Profiles in Healthy Caucasian and Japanese American Subjects. The Journal of Clinical Pharmacology. 44(3). 258–264. 18 indexed citations
14.
Sramek, John J., Mark Leibowitz, Samuel Weinstein, et al.. (2002). Efficacy and safety of sibutramine for weight loss in obese patients with hypertension well controlled by β-adrenergic blocking agents: a placebo-controlled, double-blind, randomised trial. Journal of Human Hypertension. 16(1). 13–19. 43 indexed citations
15.
Kompoliti, Katie, Charles H. Adler, Rema Raman, et al.. (2002). Gender and pramipexole effects on levodopa pharmacokinetics and pharmacodynamics. Neurology. 58(9). 1418–1422. 62 indexed citations
16.
Fuseau, Eliane, Olivier Pétricoul, Adrian Pereira, et al.. (2001). Effects of encapsulation on absorption of sumatriptan tablets: data from healthy volunteers and patients during a migraine. Clinical Therapeutics. 23(2). 242–251. 31 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Jasper Kamp Breakdown of academic impact, for papers by I. Gaertner Breakdown of academic impact, for papers by Ya Miao Breakdown of academic impact, for papers by Randall J. Mack Breakdown of academic impact, for papers by J.-J. Péré Breakdown of academic impact, for papers by G Sędek Breakdown of academic impact, for papers by Montastruc Jl Breakdown of academic impact, for papers by Didier Meulien Breakdown of academic impact, for papers by Luciane Bisognin Ceretta Breakdown of academic impact, for papers by Liara Rizzi
Rankless by CCL
2026